- Category: Approved HCV Drugs
- Published on Wednesday, 21 January 2015 00:00
- Written by Merck
Merck will stop selling its HCV protease inhibitor boceprevir (Victrelis) by December of this year, and no new patients should be started on the drug, the company announced in a recent "Dear Healthcare Professional" letter. While the first-generation HCV protease inhibitors improved the effectiveness of pegylated interferon plus ribavirin, they are no match in terms of efficacy or tolerability for the newer interferon-free combinations approved over the past 2 years.